DEEP VEIN THROMBOSISICD-10 IndicationICD-10 CodeDeep vein thrombosis NOSDVT NOS... unspecified deep veins of right lower extremityI82.401... unspecified deep veins of left lower extremityI82.402102 more rows
DVT prophylaxis can be primary or secondary. Primary prophylaxis is the preferred method with the use of medications and mechanical methods to prevent DVT. Secondary prophylaxis is a less commonly used method that includes early detection with screening methods and the treatment of subclinical DVT.
ICD-10 Code for Encounter for prophylactic measures, unspecified- Z29. 9- Codify by AAPC.
Drug therapy for DVT prophylaxis Drug prophylaxis involves use of anticoagulants. Low-dose unfractionated heparin (UFH) 5000 units subcutaneously is given 2 hours before surgery and every 8 to 12 hours thereafter for 7 to 10 days or until patients are fully ambulatory.
Patients should be assessed for the risk of thromboembolism and bleeding before the initiation of VTE prophylaxis. The decision to initiate VTE prophylaxis should be based on the patient's individual risk of thromboembolism and bleeding, and the balance of benefits versus harms.
Low-molecular-weight heparin is a relatively recent addition to the list of therapies for prophylaxis and treatment of deep venous thrombosis (DVT).
Code Z23, which is used to identify encounters for inoculations and vaccinations, indicates that a patient is being seen to receive a prophylactic inoculation against a disease. If the immunization is given during a routine preventive health care examination, Code Z23 would be a secondary code.
Encounter for other prophylactic measures "Present On Admission" is defined as present at the time the order for inpatient admission occurs — conditions that develop during an outpatient encounter, including emergency department, observation, or outpatient surgery, are considered POA.
The ICD-10 section that covers long-term drug therapy is Z79, with many subsections and specific diagnosis codes.
For outpatients, including ambulatory patients and those recently discharged from the hospital, the 2012 ACCP guidelines recommend pharmacological prophylaxis only for patients with solid tumors with additional VTE risk factors who are also at low risk for bleeding.
Apixaban, dabigatran, rivaroxaban, edoxaban, and betrixaban are alternatives to warfarin for prophylaxis or treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE). Apixaban, edoxaban, rivaroxaban, and betrixaban inhibit factor Xa, whereas dabigatran is a direct thrombin inhibitor.